Clinical course of congestive hepatopathy pre/post heart transplantation.

IF 1.9 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Wiener Klinische Wochenschrift Pub Date : 2024-05-01 Epub Date: 2023-06-28 DOI:10.1007/s00508-023-02231-2
Lorenz Balcar, Georg Semmler, Bernhard Scheiner, Albert Friedrich Stättermayer, Stefan Ćosić, Philipp Schwabl, Niema Kazem, Mattias Mandorfer, Martin Hülsmann, Andreas Zuckermann, Thomas Reiberger
{"title":"Clinical course of congestive hepatopathy pre/post heart transplantation.","authors":"Lorenz Balcar, Georg Semmler, Bernhard Scheiner, Albert Friedrich Stättermayer, Stefan Ćosić, Philipp Schwabl, Niema Kazem, Mattias Mandorfer, Martin Hülsmann, Andreas Zuckermann, Thomas Reiberger","doi":"10.1007/s00508-023-02231-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>Heart failure (HF) might lead to increased hepatic venous pressure, thereby impairing hepatic blood outflow and subsequently inducing congestive hepatopathy. We aimed to evaluate prevalence of congestive hepatopathy in patients undergoing heart transplantation (HTX) as well as their post-transplant course.</p><p><strong>Methods: </strong>Patients undergoing HTX from 2015-2020 at the Vienna General Hospital were included (n = 205). Congestive hepatopathy was defined by hepatic congestion on abdominal imaging and hepatic injury. Laboratory parameters, ascites severity, and clinical events were assessed and post-HTX outcomes evaluated.</p><p><strong>Results: </strong>At listing, 104 (54%) patients showed hepatic congestion, 97 (47%) hepatic injury, and 50 (26%) had ascites. Congestive hepatopathy was diagnosed in 60 (29%) patients, who showed more often ascites, lower serum sodium and cholinesterase activity, and higher hepatic injury markers. Mean albumin-bilirubin (ALBI)-score as well as (modified)-model for end-stage liver disease (MELD)-scores were higher in patients with congestive hepatopathy. Median levels of laboratory parameters/scores normalised after HTX, and ascites resolved in most patients with congestive hepatopathy (n = 48/56, 86%). The post-HTX (median follow-up 55.1 months) survival was 87% and liver-related events were rare (3%). Severe ascites, low cholinesterase, and MELD/MELD-XI were associated with ascites persistence/death 1‑year after HTX. Age, male sex, and severe ascites were the only independent predictors of post-HTX mortality. Both ALBI and MELD-scores were robust indicators of post-HTX survival when measured 4 weeks after HTX (ALBI log-rank test p < 0.001; MELD log-rank test p = 0.012).</p><p><strong>Conclusion: </strong>Congestive hepatopathy and ascites were mostly reversible after HTX. Liver-related scores and ascites improve prognostication in patients after HTX.</p>","PeriodicalId":23861,"journal":{"name":"Wiener Klinische Wochenschrift","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11078855/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wiener Klinische Wochenschrift","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00508-023-02231-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background and aims: Heart failure (HF) might lead to increased hepatic venous pressure, thereby impairing hepatic blood outflow and subsequently inducing congestive hepatopathy. We aimed to evaluate prevalence of congestive hepatopathy in patients undergoing heart transplantation (HTX) as well as their post-transplant course.

Methods: Patients undergoing HTX from 2015-2020 at the Vienna General Hospital were included (n = 205). Congestive hepatopathy was defined by hepatic congestion on abdominal imaging and hepatic injury. Laboratory parameters, ascites severity, and clinical events were assessed and post-HTX outcomes evaluated.

Results: At listing, 104 (54%) patients showed hepatic congestion, 97 (47%) hepatic injury, and 50 (26%) had ascites. Congestive hepatopathy was diagnosed in 60 (29%) patients, who showed more often ascites, lower serum sodium and cholinesterase activity, and higher hepatic injury markers. Mean albumin-bilirubin (ALBI)-score as well as (modified)-model for end-stage liver disease (MELD)-scores were higher in patients with congestive hepatopathy. Median levels of laboratory parameters/scores normalised after HTX, and ascites resolved in most patients with congestive hepatopathy (n = 48/56, 86%). The post-HTX (median follow-up 55.1 months) survival was 87% and liver-related events were rare (3%). Severe ascites, low cholinesterase, and MELD/MELD-XI were associated with ascites persistence/death 1‑year after HTX. Age, male sex, and severe ascites were the only independent predictors of post-HTX mortality. Both ALBI and MELD-scores were robust indicators of post-HTX survival when measured 4 weeks after HTX (ALBI log-rank test p < 0.001; MELD log-rank test p = 0.012).

Conclusion: Congestive hepatopathy and ascites were mostly reversible after HTX. Liver-related scores and ascites improve prognostication in patients after HTX.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
心脏移植前后充血性肝病的临床过程。
背景和目的:心力衰竭(HF)可能导致肝静脉压升高,从而影响肝脏血液外流,继而诱发充血性肝病。我们旨在评估心脏移植(HTX)患者充血性肝病的发病率及其移植后的病程:方法:纳入 2015-2020 年期间在维也纳总医院接受心脏移植手术的患者(n = 205)。充血性肝病的定义是腹部成像显示肝充血和肝损伤。对实验室参数、腹水严重程度和临床事件进行了评估,并对HTX后的结果进行了评价:上市时,104 例(54%)患者出现肝充血,97 例(47%)出现肝损伤,50 例(26%)出现腹水。60(29%)名患者被诊断为充血性肝病,他们更常出现腹水,血清钠和胆碱酯酶活性较低,肝损伤指标较高。充血性肝病患者的平均白蛋白胆红素(ALBI)评分和(改良)终末期肝病模型(MELD)评分均较高。HTX 后,实验室参数/评分的中位数水平趋于正常,大多数充血性肝病患者的腹水得到缓解(n = 48/56,86%)。HTX(中位随访 55.1 个月)后的存活率为 87%,与肝脏相关的事件很少发生(3%)。严重腹水、低胆碱酯酶和 MELD/MELD-XI 与 HTX 一年后腹水持续存在/死亡有关。年龄、男性和严重腹水是预测 HTX 术后死亡率的唯一独立因素。在 HTX 4 周后进行测量,ALBI 和 MELD 评分都是 HTX 后存活率的可靠指标(ALBI 对数秩检验 p 结论):HTX 后,充血性肝病和腹水大多是可逆的。肝脏相关评分和腹水可改善 HTX 后患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Wiener Klinische Wochenschrift
Wiener Klinische Wochenschrift 医学-医学:内科
CiteScore
4.70
自引率
3.80%
发文量
110
审稿时长
4-8 weeks
期刊介绍: The Wiener klinische Wochenschrift - The Central European Journal of Medicine - is an international scientific medical journal covering the entire spectrum of clinical medicine and related areas such as ethics in medicine, public health and the history of medicine. In addition to original articles, the Journal features editorials and leading articles on newly emerging topics, review articles, case reports and a broad range of special articles. Experimental material will be considered for publication if it is directly relevant to clinical medicine. The number of international contributions has been steadily increasing. Consequently, the international reputation of the journal has grown in the past several years. Founded in 1888, the Wiener klinische Wochenschrift - The Central European Journal of Medicine - is certainly one of the most prestigious medical journals in the world and takes pride in having been the first publisher of landmarks in medicine.
期刊最新文献
Gastrointestinal function and pain outcomes following segmental resection or discoid resection for low rectal endometriosis. Olfaction and thyroid hormones in patients with subjective cognitive decline, non-amnestic and amnestic mild cognitive impairment Neurofibromatosis type 1 adult surveillance form for Austria COVID-19 vaccines: anaphylaxis and anxiety Deciphering the role of lactate as a prognostic indicator in pediatric diabetic ketoacidosis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1